Tradestie Institutional Equity Comparison Engine

LCTX vs JSPR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

JSPR Overall Edge

JSPR Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Jasper Therapeutics, Inc. Common Stock (JSPR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus JSPR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against JSPR sits in UNCLASSIFIED (45th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs JSPR N/M Fwd P/E
Growth & Margin Winner JSPR
Op Margin -280.3% vs 0.0% ยท YoY -61.0% vs +0.0%
Momentum & Technical Winner JSPR
1Y -53.7% vs +487.4% ยท 52W Pos 4% vs 62%
Options & Structure Winner JSPR
BREAKDOWN (100th %ile IV) vs UNCLASSIFIED (45th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
JSPR NASDAQ
Jasper Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$10.75
-6.68% 1D
Market Cap $12.8M
1M Return +2031.67%
1Y Return +487.43%
Forward P/E N/M
Unified AI Score
33.8 / 100 SELL
Tech 50.0 Fund 34.0 Flow 70.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% JSPR +487.43% Spread: +541.1 pp (JSPR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LCTX TTM Op. Margin: -280.3% JSPR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LCTX vs JSPR. Trailing 12-month operating profitability (LCTX -280.3% vs JSPR 0.0%) and valuation multiples (LCTX 30.7x vs JSPR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (7) vs JSPR (3)
Institutional Metric LCTX JSPR Criterion Row Winner
Market Capitalization Scale $212.1M $12.8M Larger Scale LCTX
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% +0.0% Higher Growth JSPR
Operating Margin (TTM) Profitability -280.3% 0.0% Higher Margin JSPR
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -255.1% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 62% ($0โ€“$17) Stronger Trend JSPR
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol 8.00ฮฒ ยท 11818% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs JSPR Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
JSPR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 45th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live JSPR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor JSPR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.